You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Rescinnamine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for rescinnamine and what is the scope of patent protection?

Rescinnamine is the generic ingredient in two branded drugs marketed by Panray and Pfizer, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for rescinnamine.

Summary for rescinnamine

US Patents and Regulatory Information for rescinnamine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Panray CINNASIL rescinnamine CAPSULE;ORAL 084736-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Pfizer MODERIL rescinnamine TABLET;ORAL 010686-006 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Pfizer MODERIL rescinnamine TABLET;ORAL 010686-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Rescinnamine Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Rescinnamine

Overview of Rescinnamine

Rescinnamine is an angiotensin-converting enzyme (ACE) inhibitor, derived from the plant Rauwolfia serpentina and other Rauwolfia species. It is used primarily as an antihypertensive drug to treat hypertension[1].

Market Context

Current Market Status

Rescinnamine is not widely approved or commercially available in major markets. Unlike other ACE inhibitors, it does not have significant commercial presence or ongoing clinical trials, which limits its market impact[1].

Competitive Landscape

The antihypertensive market is dominated by other ACE inhibitors and more modern classes of drugs such as angiotensin II receptor blockers (ARBs) and direct renin inhibitors. These drugs have stronger market presence, better clinical trial data, and wider approval, making them more competitive than rescinnamine[1].

Financial Trajectory

Lack of Commercial Approval

Since rescinnamine is not approved in major markets like the US or Europe, it does not generate significant revenue. The absence of commercial approval and the lack of ongoing clinical trials mean that there is no substantial financial trajectory to analyze[1].

Research and Development Costs

Any potential financial investment in rescinnamine would be tied to research and development costs. However, given its limited market potential and the dominance of other antihypertensive drugs, such investments are unlikely to yield significant returns.

Comparison with Other Markets

In contrast to the growing market for GLP-1 drugs, which is expected to expand from $10 billion to $100 billion by 2030 due to their efficacy in treating obesity and other conditions, rescinnamine's market remains stagnant[3].

Mechanism of Action and Clinical Relevance

Mechanism of Action

Rescinnamine works by inhibiting the angiotensin-converting enzyme, thereby reducing the conversion of angiotensin I to angiotensin II. This leads to decreased vasoconstriction and aldosterone secretion, resulting in lower blood pressure[1].

Clinical Relevance

While its mechanism of action is well understood, the clinical relevance of rescinnamine is limited by its lack of commercial availability and the presence of more effective and widely approved alternatives.

Potential for Revival

Advances in Natural Products

There has been a renewed interest in natural products as drug candidates, especially after the Nobel Prize in Physiology or Medicine was awarded for the discovery of avermectins and artemisinin. However, this trend has not significantly impacted rescinnamine's market status[5].

Technological Advancements

Technological advancements in drug discovery, such as molecular dynamics simulations and molecular docking, could potentially revive interest in rescinnamine by identifying new targets or improving its efficacy. However, these efforts would need substantial investment and would likely face competition from more established drugs[5].

Regulatory Status

Approval and Patents

Rescinnamine does not have any approved indications or patents, which further hampers its commercial viability. The regulatory status remains unchanged, with no ongoing clinical trials or significant regulatory activities[1].

Conclusion

Rescinnamine, despite its potential as an antihypertensive drug, does not have a significant market presence or financial trajectory due to its lack of commercial approval, limited clinical trials, and the dominance of other drugs in the antihypertensive market.

Key Takeaways

  • Limited Market Presence: Rescinnamine is not commercially approved and lacks significant market presence.
  • Competitive Landscape: Dominated by other ACE inhibitors and newer classes of antihypertensive drugs.
  • Financial Trajectory: No substantial revenue generation due to lack of commercial approval.
  • Mechanism of Action: Inhibits angiotensin-converting enzyme to reduce blood pressure.
  • Clinical Relevance: Limited by the availability of more effective and widely approved alternatives.
  • Potential for Revival: Technological advancements and renewed interest in natural products could potentially revive interest, but significant investment is needed.

FAQs

Q: What is rescinnamine used for?

A: Rescinnamine is used to treat hypertension by inhibiting the angiotensin-converting enzyme.

Q: Is rescinnamine commercially available?

A: No, rescinnamine is not commercially approved in major markets.

Q: How does rescinnamine compare to other antihypertensive drugs?

A: Rescinnamine is less competitive compared to other ACE inhibitors and newer classes of antihypertensive drugs.

Q: What are the potential future developments for rescinnamine?

A: Advances in drug discovery technologies and renewed interest in natural products could potentially revive interest in rescinnamine.

Q: Why is rescinnamine not widely used?

A: The lack of commercial approval, limited clinical trials, and the dominance of other antihypertensive drugs contribute to its limited use.

Sources

  1. DrugBank: Rescinnamine: Uses, Interactions, Mechanism of Action.
  2. UTS Library: Exploring genetic engineering strategies to enable heterologous production of rescinnamine.
  3. Goldman Sachs: Weighing the GLP-1 market.
  4. MDPI: Plant-Based Indole Alkaloids: A Comprehensive Overview.
  5. Refubium: Computergestützte Methoden in der Arzneimittelentwicklung.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.